List of Tables

Table A.1. List of countries with the highest numbers of estimated cases of diabetes for 2000 and 2030 26
Table A.4. Orally administered antihyperglycemic agents (OHAs) for the treatment of diabetes. 46
Table A.5. Molecular targets in type 2 diabetes. 48
Table A.6. Gastrointestinal peptides with demonstrable effects on insulin secretion under experimental conditions 50
Table A.7. Comparison of the two strategies using GLP-1-based therapy 52
Table 2.1. Normal human dipeptidyl peptidase activity 72
Table 2.2. Assay conditions for DPP-IV enzyme and other related proteases in the screening of GRC 8011 77
Table 2.3. Inhibition of DPP-IV enzyme by GRC 8011 78
Table 2.4. Selectivity of GRC 8011 for DPP-IV enzyme over other related proteases 78
Table 3.1.1. Scheme of the dose-response study for GRC 8011 in OGTT 93
Table 3.2.1. Effect of GRC 8011 on fasting blood glucose levels- experimental design 94
Table 3.3.2.1. Schematic diagram of the experimental design 98
Table 3.4.1. Scheme of the dose-response study for GRC 8011 in OGTT in male db/db mice 99
Table 3.4.2. Scheme of the dose-response study for GRC 8011 in OGTT in ob/ob mice 100
Table 3.5.1. Schematic diagram of the experimental design 103
Table 3.6.1. Experimental design of the study 105
Table 3.7.1. Study scheme 107
Table 3.8.1. Dose-response study of GRC 8011 in OGTT in mice- AUCg 0-120 data 110
Table 3.9.1. Effect of GRC 8011 on whole blood glucose levels in 18 hour fasted C57BL/6J mice 112
Table 3.10.1.1. Pharmacodynamic effects of GRC 8011 in OGTT in C57BL/6J mice: Plasma glucose data 113
Table 3.10.1.2. Pharmacodynamics of GRC 8011 in OGTT in C57BL/6J mice: Plasma DPP-IV data 113
Table 3.10.2.1. Plain OGTT in n0-STZ rats at 8 weeks of age: Whole blood glucose (WBG) levels and AUC data 116
Table 3.10.2.2. Pharmacodynamics in a type 2 diabetic rat (n0-STZ model): Plasma glucose data during OGTT 118
Table 3.10.2.3. Pharmacodynamics in a type 2 diabetic rat (n0-STZ model): Plasma DPP-IV data during OGTT 118
Table 3.10.2.4. Pharmacodynamics in a type 2 diabetic rat (n0-STZ model): Plasma active GLP-1 data during OGTT 119
Table 3.10.2.5. Pharmacodynamics in a type 2 diabetic rat (n0-STZ model): Plasma insulin data during OGTT 119
Table 3.11.1.1. Effect of GRC 8011 on whole blood glucose levels in 18 hour fasted male db/db mice 121
Table 3.11.2.1. Effect of GRC 8011 on whole blood glucose levels in OGTT in ob/ob mice 123
Table 3.12.1. Plain OGTT in C57BL/6J mice fed with Lard control (10 kcal% lard) and HFD (45 kcal% lard) diets- WBG level data 125
Table 3.12.2. Effect of GRC 8011 in acute OGTT in HFD-fed mice-WBG data 125
Table 3.13.1. Effect of GRC 8011 on OGTT in C57BL/6J mice – WBG levels on day 14 of the study 127
Table 3.13.2. Effect of GRC 8011 on OGTT in C57BL/6J mice – WBG levels on day 56 of the study 127
Table 3.14.1. Plain OGTT in n0-STZ at 8 weeks of age: Whole blood glucose levels and AUC data 133
Table 3.14.2. Acute effect of GRC 8011 in OGTT in n0-STZ rats: Day zero of the study 133
Table 3.14.3. Acute effect of GRC 8011 in OGTT in n0-STZ rats: Day 18 of the study 134
Table 3.14.4. Chronic effect of GRC 8011 during plain OGTT in n0-STZ rats: Day 21 of the study 135
Table 3.14.5. Effect of GRC 8011 on plasma glucose levels during the course of study 136
Table 3.14.6. Effect of GRC 8011 on % HbA1c on day 28 of the study 136
Table 3.14.7. Effect of GRC 8011 on plasma triglyceride on day 28 of the study 137
Table 3.14.8. Effect of GRC 8011 on feed consumption during the course of study 137
Table 3.14.9. Effect of GRC 8011 on body weight gain during the course of study 138
Table 4.1. Plasma concentrations of GRC 8011 (10 mg/kg) during pharmacokinetic study in rats 155
Table 4.2. Pharmacokinetic profile of GRC 8011 (10 mg/kg, p.o.) in rats 156
Table 5.1.1. Experimental design of acute toxicity study 161
Table 5.1.2. Clinical signs* in the acute toxicity of GRC 8011 in Balb/C mice 164
Table 5.1.3. Effect of GRC 8011 on body weight in Balb/C mice during acute toxicity study 165
Table 5.1.4. Effect of GRC 8011 on feed consumption in Balb/C mice during acute toxicity study 166
Table 5.1.5. Acute toxicity study of GRC 8011 in Balb/C mice – Gross pathology (Macroscopic observations) 167
Table 5.2.1. Allocation of mice in subacute (28-day oral administration) toxicity study of GRC 8011 169
Table 5.2.1a. Effect of GRC 8011 on body weight in subacute (28-day oral administration) toxicity study in male mice 173
Table 5.2.1b. Effect of GRC 8011 on body weight in subacute (28-day oral administration) toxicity study in female mice 174
Table 5.2.2a. Effect of GRC 8011 on food consumption during subacute (28-day oral administration) toxicity study of GRC 8011 in male mice 175
Table 5.2.2b. Effect of GRC 8011 on food consumption during subacute (28-day oral administration) toxicity study of GRC 8011 in female mice 175
Table 5.2.3a. Effect of GRC 8011 on absolute organ weight (gm) in subacute (28-day oral administration) toxicity study in male mice 176
Table 5.2.3b. Effect of GRC 8011 on absolute organ weight (gm) in subacute (28-day oral administration) toxicity study in female mice 177
Table 5.2.4a. Effect of GRC 8011 on relative organ weight (gm) in subacute (28-day oral administration) toxicity study in male mice 178
Table 5.2.4b. Effect of GRC 8011 on relative organ weight (gm) in subacute (28-day) oral toxicity in female mice

Table 5.2.5a. Effect of GRC 8011 on plasma biochemistry in subacute (28-day oral administration) toxicity study in male mice

Table 5.2.5b. Effect of GRC 8011 on plasma biochemistry in subacute (28 day) oral toxicity in female mice

Table 5.2.6. Effect of GRC 8011 on haematological profile in subacute (28-day oral administration) toxicity study in mice

Table 5.2.6. Effect of GRC 8011 on haematological profile in subacute (28-day oral administration) toxicity study in mice

Table 5.2.6. Effect of GRC 8011 on haematology in subacute (28 day) oral toxicity in mice

Table 5.2.7a. Gross pathological findings in the subacute oral toxicity study of GRC 8011 in male mice

Table 5.2.7b. Gross pathological findings in the subacute oral toxicity study of GRC 8011 in female mice

Table 5.2.8. Summary of histopathological findings of subacute (28-day oral administration) toxicity study of GRC 8011 in mice

Table 6.1.1. Scheme of the study of GRC 8011 on food intake in rats

Table 6.1.2. Effect of GRC 8011 on food intake in fasted rats

Table 6.2.1. Effect of GRC 8011 on intestinal transit of charcoal meal in mice

Table 6.3.1. Effect of GRC 8011 on gastric emptying in rats by paracetamol absorption method

Table 6.4.1. Effect of GRC 8011 on body weight in Zucker fa/fa rats

Table 6.4.2. Effect of GRC 8011 on feed consumption in Zucker fa/fa rats

Table 6.4.3. Effect of GRC 8011 on plasma cholesterol in diet-induced obese mice

Table 6.4.4. Effect of GRC 8011 on body weight in diet-induced obese mice

Table 6.4.5. Effect of GRC 8011 on feed consumption in diet-induced obese mice